Infections With Enterobacteria Producing Carbapenemases at the University Hospitals of Strasbourg

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

274 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-08-06

Study Completion Date

2022-01-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Infections with enterobacteria producing carbapenemases at the University Hospitals of Strasbourg - descriptive epidemiology and risk factors for infection in the event of colonization

There is a worrying situation of an increase in the number of patients colonized with carbapenemase-producing Enterobacteriaceae (CPE) at HUS.

7 to 15% of patients colonized with EPC would develop an infection with EPC. The cohorts published mainly concern patients hospitalized in intensive care. The associated mortality reported in the literature is high (\> 25%) and greater than that associated with infection with the same bacterium sensitive to carbapenems.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Carbapenem Antibiotic Therapy for VIM Carbapenemase-Producing Enterobacteriaceae Infections

NCT06185153

Carbapenemase-Producing Enterobacteriaceae

RECRUITING

Rectal Carriage of Carbapenemase Producing-Enterobacteriaceae on Admission to a French University Teaching Hospital

NCT05798351

Rectal Carriage of Carbapenemase Producing-Enterobacteriaceae

RECRUITING

Epidemiology of Carbapenemase-producing Bacteria in a Swiss Tertiary Care Hospital

NCT04098133

Infections With CPB

RECRUITING

Prevalence of Clinical Strains of Enterobacteria With Reduced Susceptibility to Carbapenems in the North-West Region of France

NCT02799225

Enterobacteriaceae

COMPLETED

Carbapenem-resistant Enterobacteriaceae: Prevalence, Risk Factors and Impact of the Use of the Phenotypic Algorithm for the Detection of Carbapenemases

NCT02127450

Enterobacteria Non Susceptible to Carbapenem Carrier Enterobacteria Susceptible to Carbapenem Carrier

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Nfections, Enterobacterial

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Major subject (≥18 years old)
* Subject hospitalized at HUS between 01/01/2011 and 07/31/2021
* Clinical sample or rectal screening smear finding an enterobacterium producing a carbapenemase (EPC)
* Subject not having expressed their opposition to participating in the study